Oxford Biomedica plc announced that CDMO expert, Peter Soelkner, will join the Board as a Non-Executive Director, effective from 15 March 2024. Concurrently, as part of Oxford Biomedica's transformation into a pure-play CDMO, the Company announced that Catherine Moukheibir and Dr. Michael Hayden have informed the Board that they do not intend to stand for re-election at the upcoming Annual General Meeting in June 2024. Dr. Michael Hayden will continue to be an adviser to the Science and Technology Advisory Committee.

Peter Soelkner has more than 30 years' experience in the global pharmaceutical services industry with significant CDMO expertise. He is currently Managing Director of Vetter Pharma. Prior to Vetter, Mr. Soelkner held various senior positions at Sartorius including Vice President of the Americas region where he expanded the global footprint of the business across the US and multiple sectors.

He has an MBA from Columbia Business School, New York and Masters in Chemical Engineering from TU Dortmund University, Germany.